


Product Name : BTX-1188
Cat. No. : PC-23063
CAS No. : 2560577-69-5
Molecular Formula : C₂₆H₂₂F₃N₃O₅
Molecular Weight : 513.47
Target : PROTAC
Solubility : 10 mM in DMSO



CAS: 2560577-69-5

Biological Activity

Sontigidomide (BTX-1188) is a first-in-class dual degrader of **GSPT1** and **IKZF1/3** with DC50 of 0.2 nM, 1 nM and 1 nM for GSPT1, IKZF1 and IKZF3 respectively, in DOHH-2 (lymphoma) cells.

BTX-1188 potently inhibits AML and solid tumor cell proliferation.

Sontigidomide (BTX-1188) potently inhibits aCD3-stimulated and LPS-induced cytokine induction in human PBMCs.

BTX-1188 is cytotoxic in various cancer cell lines such as MYC-dependent and non-MYC dependent lines (IC50 range: 0.5-20 nM) and primary human AML patient samples (IC50 range: 0.4-1.5 nM), including relapsed/refractory-, cytarabine and Venetoclax-resistant samples.

BTX-1188 (25 mg/kg, i.p. QD) is highly efficacious in NCI H1155 (NSCLC) xenograft model in BALB/c nude mice.

References

Patent US20200369679 A1

Aparajita Hoskote Chourasia, et al. Meeting Abstract: 2022 ASCO Annual Meeting I

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com